B+labs at Cira Centre Fully Occupied and Open
Life science incubator space expands Brandywine’s Life Science platform in the Greater Philadelphia Area
Philadelphia, May 9, 2022 — Today, Brandywine Realty Trust (NYSE: BDN) and Pennsylvania Biotechnology Center (PABC) announce B+labs at Cira Centre is not only open but fully leased. The list of life science leaders occupying the B+labs community includes 3D Systems, Asklepios Biopharmaceutical (AskBio), BriaCell Therapeutics Corp., Carisma Therapeutics, Ceptur Therapeutics, Quanta Therapeutics, Synapticure, Tmunity Therapeutics, Vetigenics, and Vitara Biomedical, among others.
“The level of activity in Philadelphia and B+labs in particular is starting to feel like Cambridge and the Kendall Square area in Boston. We are thrilled to be here,” said Felipe Bedoya, Director of Cell Engineering and Gene Editing at Tmunity Therapeutics.
“The science behind the companies at B+labs is impressive, and we are excited to support their discovery and development efforts. It is a formidable group here,” said Matthew Burkhardt, Director of B+labs. “Over 40% of the companies in B+labs are new to the Region. These companies now have the ability to tap into and attract the area’s expansive talent base and the opportunity to be a part of the burgeoning local life science community and rapidly growing ecosystem,” said Jeff DeVuono, Executive Vice President and Regional Managing Director at Brandywine Realty Trust.
B+labs is a part of Brandywine’s diverse life science real estate portfolio ranging from incubator and graduate space to build-to-suit lab and research space. Brandywine’s portfolio includes more than three million square feet of life science space within its master-planned Schuylkill Yards neighborhood and an additional 1 million square feet in the greater Philadelphia region. Near-term opportunities within the Brandywine Life Sciences platform include:
- Cira Centre: Floors five through nine will provide up to 150,000 square feet of additional life science space
- 3025 JFK: A mixed-use development with 200,000 square feet of office and dedicated life science space, delivering Q3 2023
- 3151 Market: A ground-up fully dedicated life science building with options for full floors of intensive biological and chemical lab use, delivering Q3 2024
- 250 Radnor Life Science Center: A 160,000 square feet life science development in Radnor, PA being delivered Q3 2022
Companies interested in joining the B+labs community may join a waitlist until there is available space. For additional information, visit www.brandywinerealty.com/blabs.
About Brandywine Realty Trust: Brandywine Realty Trust (NYSE: BDN) is one of the largest, publicly traded, full-service, integrated real estate companies in the United States with a core focus in the Philadelphia, Austin and Washington, D.C. markets. Organized as a real estate investment trust (REIT), we own, develop, lease and manage an urban, town center and transit-oriented portfolio comprising 168 properties and 23.1 million square feet as of December 31, 2021 which excludes assets held for sale. Our purpose is to shape, connect and inspire the world around us through our expertise, the relationships we foster, the communities in which we live and work, and the history we build together. For more information, please visit www.brandywinerealty.com.
About the Pennsylvania Biotechnology Center (PABC): The PABC is a nonprofit life sciences incubator-accelerator, offering state-of-the-art laboratory and office space to early stage biotech companies, as well as the Hepatitis B Foundation and Blumberg Institute. Managed by the Institute and led by a board appointed by the Foundation, PABC is home to nearly 50 small to mid-size science, research and pharmaceutical companies. The center uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries that will make a difference. PABC is near Doylestown in Bucks County, in the heart of the Philadelphia-New Jersey pharma belt. For more information, please visit www.pabiotechbc.org.